September 22nd 2023
The first-line combination of pembrolizumab, lenvatinib, pemetrexed, and platinum-containing chemotherapy did not meet the dual primary end points of overall survival and progression-free survival compared with pembrolizumab plus pemetrexed and platinum-containing chemotherapy in patients with metastatic, nonsquamous non–small cell lung cancer in whom EGFR-, ALK- or ROS1-directed therapies were not indicated.
September 22nd 2023
25th Annual International Lung Cancer Congress®
Register Now!
Advances In™: Meeting Unmet Clinical Needs in AML with Evolving Therapeutic Approaches
View More
Reflective Case-Based Oncology Collective: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Bridging the Care Gap in Anemia in CKD: A Comprehensive Guide to Enhancing Patient Care
Register Now!
Antibody-Drug Conjugates in Gynecological Cancer – Setting the Stage
View More
Community Practice Connections™: Chronic Fibrosing ILDs With Progressive Phenotype–Are You Aware of the Latest Data on Diagnosis and Emerging Treatments?
View More
Catching Them Early: A Real-World Case Discussion on the Application of Testing Methodologies to Identify Key Markers Across NSCLC
View More
Shaping the Management of Multiple Sclerosis – The Potential for BTK Inhibitors in Clinical Practice
View More
Anemia of Chronic Kidney Disease: Improving Recognition and Early Treatment in the Primary Care Setting
View More
Transforming Multiple Sclerosis Care – Clinical Updates on the Effects of BTK Inhibitors
10/13/2023
Register Now!
20th Annual Meeting of the International Society of Gastrointestinal Oncology®
Register Now!
Advances In™ Pediatric Neuroblastoma: Exploring Current and Emerging Therapeutic Approaches for Relapsed/Refractory Disease and CNS Metastases
View More
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
Clinical Consultations: Individualizing Management of Uveitic Macular Edema - Clinical Updates in Treatment Options
View More
From Clinical Trials to Clinical Practice – Incorporating Screening and Assessment Strategies for the Early Diagnosis of Alzheimer Disease
View More
5th Annual Precision Medicine Symposium: An Illustrated Tumor Board
Register Now!
Taking Pompe Disease Management to the Next Level: Optimizing Clinical Assessments and Treatment Decision-Making
View More
Evaluating the Evolution of CKD Treatment: What’s New and How Can We Incorporate It?
View More
2022 BURST Year in Review™: Reflecting on Recent Evidence for Testing in Patients with GI Cancers
View More
2nd Annual International Congress on Pediatric Oncology
View More
2022 BURST Year in Review™: How Has Recent Evidence in Testing Elevated Outcomes in Patients with Lung Cancers
View More
4th Annual Virtual Tumor Board®: Diagnosis and Management of Polycythemia Vera and Myelofibrosis
View More
Burst CME: Regulatory Approval Pathways for Influenza Vaccines
View More
Medical Crossfire®: Experts Address Your Burning Questions on the Evolving Treatment of MF, PV, and ET!
View More
Burst CME: Selecting an Appropriate Influenza Vaccine for Adults 65 Years and Older
View More
Expanding Options Beyond Conventional Therapy in HR+ Breast Cancer to Overcome Unmet Needs
View More
Community Practice Connections™: 23rd Annual International Lung Cancer Congress®
View More
21st Annual School of Breast Oncology
Register Now!
Oncology Consultations®: Leveraging Clinical Data and Trials to Inform Treatment for Patients with PV
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow®
Register Now!
Preoperative APL-1202 Plus Tislelizumab Meets pCR Criteria, Moves to Next Stage of Trial in MIBC
September 13th 2023The Safety Monitoring Committee determined that prespecified criteria for pathologic complete response were met with the use of the PD-1 inhibitor tislelizumab alone or in combination with APL-1202 as neoadjuvant therapy in patients with muscle invasive bladder cancer.
Subgroup Observations From Missed KEYNOTE-789 Data in NSCLC Provide Insight for the Future
September 4th 2023James Chih-Hsin Yang, MD, PhD, discusses the implications of the phase 3 KEYNOTE-789 trial and what directions investigators can examine in the future to help fill the unmet need for patients with TKI-resistant, EGFR-mutated metastatic non–small cell lung cancer.
PRGN-2009 Plus Bintrafusp Alfa Shows Early Activity in HPV-Associated Malignancies
James L. Gulley, MD, PhD, reviews the safety and efficacy of PRGN-2009 alone and in combination with bintrafusp alfa in HPV-associated cancers and explains how this kind of approach may address an unmet clinical need.
Cracking the Immunotherapy Code Remains a Challenge in Ovarian Cancer
Martin Cannon, PhD, details the history of investigating immune checkpoint inhibitors in patients with ovarian cancer and expands on the questions that need to be answered to potentially improve the activity of these agents in this patient population.
Subcutaneous Atezolizumab Approved in Great Britain for All Intravenous Indications
Great Britain’s Medicines and Healthcare Products Regulatory Agency has approved subcutaneous atezolizumab for all indications in which the intravenous formulation of the drug has been approved, including select types of lung, bladder, breast, and liver cancers.
Pembrolizumab With COPDAC-28 Consolidation Increases PET Negativity in Classical Hodgkin Lymphoma
The addition of pembrolizumab to COPDAC-28 consolidation may augment responses to treatment in pediatric and young adult patients with high-risk classical Hodgkin lymphoma who experience a slow early response to frontline chemotherapy.
LEAP-010 Trial Discontinued After OS Projection With Pembrolizumab/Lenvatinib in Metastatic HNSCC
August 25th 2023The combination of pembrolizumab and lenvatinib demonstrated a statistically significant improvement in progression-free survival and objective response rate but failed to improve overall survival compared with pembrolizumab plus placebo as frontline therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma.
Atezolizumab Plus Cabozantinib Improves PFS in Hormone Therapy–Pretreated mCRPC
August 21st 2023The combination of cabozantinib and atezolizumab led to a statistically significant improvement in progression-free survival compared with a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer and measurable soft tissue disease following 1 prior novel hormonal therapy, meeting one of the primary end points in the primary analysis of the phase 3 CONTACT-02 trial.
Avelumab Increases PFS Rates in dMMR/MSI Metastatic CRC
Patients with mismatch repair–deficient and/or microsatellite instability metastatic colorectal cancer experienced a progression-free survival benefit with longer disease control following treatment with avelumab compared with standard second-line chemotherapy.
GVAX Cancer Vaccine Plus Nivolumab and Urelumab Elicits Early Efficacy in Pancreatic Adenocarcinoma
Treatment with the GVAX pancreatic cancer vaccine plus nivolumab and urelumab increased the presence of intratumoral activated cytotoxic T cells and showed early signs of efficacy in patients with resectable pancreatic adenocarcinoma.
MDNA11 Generates Activity, Safety in Advanced Solid Tumors
Treatment with the long-acting interleukin-2 superkine led to durable tumor control and no dose-limiting toxicities in patients with advanced solid tumors, according to data from the dose-escalation portion of the phase 1/2 ABILITY-1 trial.
Pembrolizumab Generates Sustained Responses in Relapsed/Refractory PMBCL
Pembrolizumab produced sustained antitumor activity in patients with relapsed/refractory primary mediastinal large B-cell lymphoma, according to data from the final analysis of the phase 2 KEYNOTE-170 trial.
Investigators Pursue the Role of the Microbiome on Immunotherapy Treatment in RCC
Pedro C. Barata, MD, MSc, discusses the importance of further exploring the facets of manipulating the microbiome to augment responses with immunotherapy in RCC, as well as the promise of the bifidogenic live bacterial product, CBM588.
PD-1 Inhibitors Demonstrate Promise as Salvage Therapy in R/R Extranodal NK/T-cell Lymphoma
July 31st 2023Amira Marouf, MD, PhD student, describes the nature of a comparative analysis conducted based on propensity score matching, and discussed the main takeaways regarding the efficacy of PD-1 inhibitors for patients with relapsed/refractory ENKTCL.
Long-Term Data Show Improved CR Rates for Cosibelimab in Advanced CSCC
Long-term data demonstrated that treatment with cosibelimab improved complete response rates over time in patients with locally advanced or metastatic cutaneous squamous cell carcinoma in a phase 1 trial.
mRNA-4157 Plus Pembrolizumab Under Further Investigation in Phase 3 Trial in High-Risk Melanoma
The combination of mRNA-4157 and pembrolizumab will be further evaluated as an adjuvant treatment option for patients with resected, high-risk, stage IIB to IV melanoma in the phase 3 V940-001 trial.
First-Line Rivoceranib Plus Camrelizumab Improves Survival in Unresectable HCC
Treatment with the combination of rivoceranib and camrelizumab led to a statistically significant and clinically meaningful benefit in progression-free survival and overall survival compared with sorafenib in previously untreated patients with unresectable hepatocellular carcinoma.
Evaluating Toxicities of Antineoplastic Drug Therapeutics: Is It Time for a Critical Review?
July 24th 2023An evaluation of the utility of a cancer therapeutic in a clinical trial is determined through metrics that define 2 distinctive features of an antineoplastic strategy: efficacy and toxicity. Although that may be an oversimplification, the aim of such therapy is to improve clinical outcomes.
Treatment with the combination of ENB-003 and pembrolizumab was well tolerated and produced preliminary signs of clinical activity in patients with platinum-refractory or -resistant, microsatellite stable ovarian cancer, and those with other advanced refractory solid tumors.
Tislelizumab Plus Bevacizumab/Chemo Demonstrates Early Efficacy in Cervical Cancer
July 20th 2023The addition of the PD-L1 inhibitor tislelizumab to standard bevacizumab and platinum-doublet chemotherapy in the first-line setting prolonged progression-free survival, produced encouraging responses, and was well tolerated in patients with cervical cancer.
Setanaxib Plus Pembrolizumab Elicits PFS Benefit in Recurrent or Metastatic HNSCC
The combination of the NOX1/4 inhibitor setanaxib and pembrolizumab produced progression-free survival benefits compared with placebo plus pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma.